Editas Medicine (EDIT) Change in Account Payables (2015 - 2025)
Editas Medicine (EDIT) reported Change in Account Payables of -$3.6 million for Q3 2025, down 183.97% year-over-year from $4.2 million in Q3 2024, and down 383.07% quarter-over-quarter from $1.3 million in Q2 2025.
Editas Medicine (EDIT) Change in Account Payables (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 11 years of Change in Account Payables data on file, last reported at -$3.6 million in Q3 2025.
- Change in Account Payables for Q3 2025 came in at -$3.6 million, down 183.97% year-over-year; the trailing twelve-month figure through Sep 2025 was -$9.3 million (down 540.25% YoY), and the FY2024 annual result was -$2.3 million, down 53.22% from the prior year.
- Change in Account Payables declined to -$3.6 million in Q3 2025 per EDIT's latest filing, from $1.3 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $7.4 million in Q2 2024 and troughed at -$7.0 million in Q4 2024.
- A 5-year average of -$151526.3 and a median of -$229000.0 in 2022 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables sank 196.29% in 2023, then soared 1161.95% in 2024.
- A 5-year view of Change in Account Payables shows it stood at $1.8 million in 2021, then surged by 46.49% to $2.7 million in 2022, then slumped by 196.29% to -$2.6 million in 2023, then tumbled by 169.81% to -$7.0 million in 2024, then surged by 49.12% to -$3.6 million in 2025.
- Business Quant data shows EDIT's Change in Account Payables at -$3.6 million in Q3 2025, $1.3 million in Q2 2025, and -$27000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.56 Mn |
| Sep 30, 2025 | -3.56 Mn |
| Jun 30, 2025 | 1.26 Mn |
| Jun 30, 2025 | 1.26 Mn |
| Mar 31, 2025 | -27,000.00 |
| Mar 31, 2025 | -27,000.00 |
| Dec 31, 2024 | -7.00 Mn |
| Dec 31, 2024 | -7.00 Mn |
| Sep 30, 2024 | -1.25 Mn |
| Sep 30, 2024 | -1.25 Mn |
| Jun 30, 2024 | 7.42 Mn |
| Jun 30, 2024 | 7.42 Mn |
| Mar 31, 2024 | -1.46 Mn |
| Mar 31, 2024 | -1.46 Mn |
| Dec 31, 2023 | -2.59 Mn |
| Dec 31, 2023 | -2.59 Mn |
| Sep 30, 2023 | 2.36 Mn |
| Sep 30, 2023 | 2.36 Mn |
| Jun 30, 2023 | -699,000.00 |
| Jun 30, 2023 | -699,000.00 |